News | April 15, 2026
FDA presses 2,200+ companies to fix missing clinical trial results
Move amid evidence of widespread reporting gaps
Move amid evidence of widespread reporting gaps
CRDMO plans to add 800–1,000 women across scientific and leadership roles over three years
The programme features headline data from pivotal Phase III trials, including PREVAIL in gMG, KOMET in NF1-PN, and CHAMPION-NMOSD, alongside real-world evidence supporting established therapies
Backed by funding from an NIHR Doctoral Award, the guidance is focused on spotting abdominal tumours
Paves the way for next-gen ultra-precise gas sensing
A major push to sharpen the future of cancer treatment is underway
The launch saw the presence of senior clinicians and leadership from the Manipal Hospitals network
Scientists at the forum warned of an increasingly volatile health landscape
BioNTech will supply pumitamig, a PD-L1/VEGF-A bispecific antibody co-developed with Bristol Myers Squibb, while Boehringer Ingelheim will act as the regulatory sponsor of a Phase Ib/II study
The study’s multi-technology design is intended to improve reproducibility, strengthen regulatory-grade evidence generation
Subscribe To Our Newsletter & Stay Updated
